Back to Search Start Over

Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals

Authors :
Christian Dopfer
Georg M. N. Behrens
Alexander Horke
Alexandra Jablonka
Anh Thu Tran
Christine Happle
Moritz Z. Kayser
Hendrik Streeck
Theresa Graalmann
Anne Cossmann
Anna Zychlinsky Scharff
Isabell Pink
Berislav Bošnjak
Reinhold Förster
Torsten Witte
Metodi V. Stankov
Martin Wetzke
Thea Thiele
Anna-Lena Boeck
Stefanie Willenzon
Bianca Schulte
Diana Ernst
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.
Source :
Infectious Diseases and Therapy, Vol 9, Iss 4, Pp 837-849 (2020), Infectious diseases and therapy, New Zealand, Infectious Diseases and Therapy
Publication Year :
2020
Publisher :
Adis, Springer Healthcare, 2020.

Abstract

Background Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2. Results From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p

Details

Language :
English
ISSN :
21936382 and 21938229
Volume :
9
Issue :
4
Database :
OpenAIRE
Journal :
Infectious Diseases and Therapy
Accession number :
edsair.doi.dedup.....c6cea60846514fadb19142fbfadc170b